AMGN

CNBC's Jim Cramer pushed viewers away from the usual semiconductor and hyperscaler chatter.

On CNBC's Mad Dash segment on Monday, July 6, 2026, Jim Cramer made one of his most bullish biotech calls in years, arguing that the sector could be entering a new wave of mergers and acquisitions as the regulatory environment becomes more favorable for dealmaking.

Amgen (AMGN) closed the most recent trading day at $366.44, moving 2.06% from the previous trading session.

Amgen (AMGN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

A federal judge on Wednesday blocked Colorado ​from capping the price of Amgen's blockbuster arthritis drug Enbrel, a first-of-its-kind ‌move by a U.S. state.

AMGN stands out compared to Biogen given its broader product portfolio, pipeline depth and steadier growth outlook despite patent and competition risks.

Medicare's new GLP-1 coverage could expand access to weight-loss drugs, making ETFs a diversified way to tap growth across the obesity treatment market.

Amgen (AMGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

The New England Journal of Medicine on Monday retracted an article on a pivotal clinical trial that supported approval of Amgen's ​rare-disease drug, citing concerns that patient outcome data were altered and ‌that some researchers had been unblinded.

The European Medicines Agency on ‌Friday recommended revoking the marketing authorisation for Amgen's rare autoimmune disease drug, ​Tavneos, citing a lack of ​benefits that outweigh its risks.